‘We’re not that com­pa­ny’: John Hood is build­ing a biotech the old-fash­ioned way — and not just be­cause he has ...

4 years ago
Financing

Covid-19 roundup: Ox­ford vac­cine sci­en­tist says overblown safe­ty fears caused death of 'hun­dreds of thou­sand­s'; ...

4 years ago
Coronavirus

Er­ic Lan­der 'bul­lied and de­meaned' staff at White House sci­ence of­fice — in­ves­ti­ga­tion

4 years ago
People

Gen­mab, Seagen want cer­vi­cal can­cer to be seen in new 'Ce­Me' cam­paign along with pa­tient ad­vo­cates

4 years ago
Pharma
Marketing

FDA restarts do­mes­tic drug man­u­fac­tur­ing in­spec­tions

4 years ago
FDA+
Manufacturing

In up­hold­ing Mar­tin Shkre­li's life­time ban, judge rules any state­ment he makes about phar­ma could be a vi­o­la­tion

4 years ago
People
Pharma

How re­searchers can get a han­dle on the mon­key short­age for tox stud­ies: FDA ex­plains

4 years ago
R&D
FDA+

R&D heads play phar­ma mu­si­cal chairs; Shat­tered block­buster dreams; Death of Aduhelm?; and more

4 years ago
Weekly

Af­ter some lengthy de­lays, Sanofi gets the FDA's OK for a rare dis­ease drug

4 years ago
Pharma
FDA+

Sen­ate Fi­nance chair asks Rob Califf for more de­tails around po­ten­tial ac­cel­er­at­ed ap­proval re­forms

4 years ago
FDA+

Vas Narasimhan and Sev­erin Schwan each claimed pay pack­ets worth $12M+ for 2021

4 years ago
Pharma

BioN­Tech wait­ed to col­lect its $100M PRV un­til just be­fore Mod­er­na's Covid-19 vac­cine ap­proval

4 years ago
FDA+

Bris­tol My­er­s' Caforio: CELMoDs have po­ten­tial to re­place Revlim­id and Po­m­a­lyst as block­busters start to lose ...

4 years ago
R&D
Pharma

With thou­sands of jobs on the chop­ping block, 'noth­ing's off the table' at Sanofi. What's stay­ing and what's go­ing?

4 years ago
Pharma

Re­gen­eron looks to George Yan­copoulos' R&D arm — and part­ners — in hunt for its next big cash cows

4 years ago
R&D
Pharma

Pfiz­er lands on For­tune’s most ad­mired list, edg­ing out Dis­ney, Google and Star­bucks in an­nu­al rep­u­ta­tion rank­ing

4 years ago
R&D

Or­chard se­cures re­im­burse­ment for gene ther­a­py; UK fines drug­mak­ers $47M for an­ti­com­pet­i­tive scheme

4 years ago
News Briefing

Van­da's gas­tric drug flops in late-stage test, crash­ing the biotech's stock

4 years ago
R&D

Watch out, As­traZeneca: UCB un­corks late-stage suc­cess for $2.1B Soliris ri­val

4 years ago
R&D

Bay­er bails on chron­ic cough drug from Evotec, putting the ki­bosh on lead med in mul­ti-tar­get col­lab­o­ra­tion

4 years ago
Deals
R&D

SEC and FTC open two more in­ves­ti­ga­tions in­to Bio­gen's con­tro­ver­sial Alzheimer's drug ap­proval and mar­ket­ing ...

4 years ago
Pharma

With fin­ish line in sight, Brig­gs Mor­ri­son steps aside from Syn­dax CEO seat, swaps role with long­time col­league

4 years ago
People

Biotech bear mar­ket be damned, CAR-T play­er Ar­cel­lx rais­es $123M IPO

4 years ago
Financing
Cell/Gene Tx

Lyell CSO: New job is 'the miss­ing piece' of his ca­reer; Or­p­hazyme and Cor­texyme and Sio, oh my: Your guide to the ...

4 years ago
Peer Review
First page Previous page 579580581582583584585 Next page Last page
A service from the Financial Times